Active Ingredient History
Apixaban is an orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clots. Apixaban has been available in Europe since May 2012. An FDA decision on apixaban which was expected on June 28, 2012 was initially delayed before final approval on December 28, 2012. On August 21, 2014, Pfizer announced that apixaban was now FDA approved for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is being developed in a joint venture by Pfizer and Bristol-Myers Squibb. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Embolism and Thrombosis (approved 2012)
Acute Coronary Syndrome (Phase 4)
Anemia, Sickle Cell (Phase 3)
Aneurysm (Phase 3)
Ankle Injuries (Phase 4)
Anticoagulants (Phase 4)
Antiphospholipid Syndrome (Phase 4)
Aortic Stenosis, Subvalvular (Phase 3)
Aortic Valve Disease (Phase 4)
Aortic Valve Stenosis (Phase 3)
Appendix (Phase 4)
Arrhythmia, Sinus (Phase 2)
Arterial Occlusive Diseases (Phase 3)
Arthroplasty, Replacement, Knee (Phase 2)
Astrocytoma (Phase 2)
Atrial Flutter (Phase 4)
Bariatric Surgery (Phase 4)
Blood Coagulation (Phase 1)
Cardiovascular Diseases (Phase 3)
Cerebral Hemorrhage (Phase 3)
Cerebral Intraventricular Hemorrhage (Phase 3)
Cerebrovascular Disorders (Phase 3)
Chronic Limb-Threatening Ischemia (Phase 3)
Colitis, Ulcerative (Early Phase 1)
Coronary Artery Bypass (Phase 2/Phase 3)
COVID-19 (Phase 4)
Crohn Disease (Early Phase 1)
Death (Phase 3)
Diabetes Mellitus (Phase 4)
Drugs, Investigational (Phase 3)
Electric Countershock (Phase 3)
Embolic Stroke (Phase 3)
Embolism (Phase 2/Phase 3)
Factor Xa (Phase 2)
Fasting (Early Phase 1)
Fibrinolytic Agents (Phase 1)
Fibrosis (Phase 4)
Foramen Ovale, Patent (Phase 3)
General Surgery (Phase 4)
Genital Neoplasms, Female (Phase 2)
Glioblastoma (Phase 2)
Glomerulonephritis, Membranous (Phase 1)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 2)
Hematoma (Phase 3)
Hematoma, Subdural (Phase 3)
Hemodialysis, Home (Phase 4)
Hemorrhage (Phase 4)
Hospitalization (Phase 3)
Hypertension, Portal (Phase 4)
Hypertrophy, Left Ventricular (Phase 4)
Inflammatory Bowel Diseases (Early Phase 1)
Intestinal Diseases (Early Phase 1)
Intracranial Hemorrhage, Hypertensive (Phase 3)
Intracranial Hemorrhages (Phase 3)
Ischemia (Phase 1/Phase 2)
Ischemic Attack, Transient (Phase 4)
Ischemic Stroke (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 4)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Liver Cirrhosis (Phase 2)
Lung Transplantation (Phase 4)
Lymphoma (Phase 3)
Medication Adherence (Phase 4)
Menstruation (Phase 2/Phase 3)
Migraine Disorders (Phase 3)
Multiple Myeloma (Phase 4)
Mutation (Phase 2)
Myeloproliferative Disorders (Phase 2)
Myocardial Infarction (Phase 3)
Myocardial Ischemia (Phase 4)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 4)
Nephrotic Syndrome (Phase 1/Phase 2)
Obesity (Phase 4)
Pancreatic Neoplasms (Phase 1)
Peritoneal Dialysis (Phase 1)
Pharmacokinetics (Phase 4)
Polycythemia Vera (Phase 2)
Postoperative Complications (Phase 2/Phase 3)
Primary Myelofibrosis (Phase 2)
Proteinuria (Phase 1)
Renal Insufficiency (Phase 3)
Renal Insufficiency, Chronic (Phase 4)
Risk Factors (Phase 1)
SARS-CoV-2 (Phase 4)
Short Bowel Syndrome (Phase 4)
Spinal Cord Injuries (Phase 2)
Splenectomy (Phase 4)
Stroke ()
Subarachnoid Hemorrhage (Phase 3)
Tachycardia, Ventricular (Phase 4)
Takotsubo Cardiomyopathy (Phase 2)
Thrombocythemia, Essential (Phase 2)
Thrombocytopenia (Phase 2)
Thromboembolism (Phase 4)
Thrombosis (Phase 4)
Upper Extremity Deep Vein Thrombosis (Phase 4)
Venous Thromboembolism (Phase 4)
Ventricular Dysfunction, Right (Phase 4)
Ventricular Premature Complexes (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
